1 results match your criteria: "and CESifo Columbia University[Affiliation]"
The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017.
Expert Rev Pharmacoecon Outcomes Res
June 2021
Graduate School of Business, Columbia University (New York, NY, USA), National Bureau of Economic Research, and CESifo Columbia University, New York, NY, USA.
Background: We investigate whether the cancer sites that experienced more pharmaceutical innovation in New Zealand had larger subsequent declines in premature mortality and hospitalization rates and larger subsequent increases in 5-year survival rates, controlling for changes in incidence.
Research Design And Methods: We estimate the effects of the number of WHO ATC5 chemical substances and ATC4 chemical subgroups approved on the number of years of potential life lost before ages 85, 75, 65, 5-year relative survival rates, and the number of inpatient hospital discharges, by estimating difference-in-differences (2-way fixed-effects) models using aggregate longitudinal data on 23 cancer sites.
Results: Substances/subgroups approved during 1985-2001 reduced the number of years of potential life lost before age 85 (YPLL85) in 2017 by 67%.